TerminatedPhase 4

Study to Test the Combination of Voriconazole and Anidulafungin in Patients Who Have, or Are Thought to Have, Invasive Aspergillosis and Who Are Unable to Take a Common Antifungal Therapy (Polyene)

Stopped: See Detailed Description

United States6 participantsStarted 2008-08

Plain-language summary

This study will test the effectiveness and the safety of giving two antifungal agents (voriconazole and anidulafungin) together to treat invasive aspergillosis in patients who are unable to tolerate polyene therapy.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: Proven or probable invasive aspergillosis. Patient is intolerant to polyene therapy. Exclusion Criteria: Patients with invasive aspergillosis for more than 30 days at the time of study entry. Patients with uncontrolled bacterial or viral infection at the time of study entry. Patients with significant liver dysfunction or who are taking certain medications which interact with voriconazole.

What they're measuring

Summary of Global Response at End of Treatment (EOT)

Timeframe: End of Treatment (Day 42)

Trial details

NCT IDNCT00620074

SponsorPfizer

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2009-02

Results submitted2010-01-21

View on ClinicalTrials.gov More Aspergillosis trials